Wed Sep 24 10:24:41 SGT 2014  
    Genital warts treatment, Singapore (SG)
Within 3 days after unprotected sex, stop HIV infection with Post-Exposure Prophylaxis treatment 10 days after unprotected sex, detect HIV infection with the DNA test 28 days after unprotected sex, accurately detect HIV infection with the 20 minute rapid test
Full & comprehensive sexually transmitted disease testing
Males: do not urinate for at least 4 hours before arriving
Females: testing is more accurate when you are not menstruating

Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™


Genital warts treatment, Singapore (SG) | HIV STD TESTING SINGAPORE™ @singaporegenital_com: Genital warts (condyloma, condylomata acuminata, venereal wart, anal wart, anogenital wart, "cauliflower" sex disease) screening/diagnosis, testing/check treatment/removal/cure, Singapore. Private and confidential service. Definitions, references, and latest news.


Genital warts: penile warts / vaginal warts / anal warts / anogenital warts / venereal warts / condyloma / condylomata acuminata / "cauliflower" sex disease.


Advertisement: Come to sunny Singapore to have your testing and treatment. Singapore Ministry of Health registered general practice (GP) clinic:
168 Bedok South Avenue 3 #01-473
Singapore 460168
Tel: (+65) 6446 7446
Fax: (+65) 6449 7446
24hr Answering Tel: (+65) 6333 5550
Web: Genital warts treatment, Singapore (SG)
Opening Hours
Monday to Friday: 9 am to 3 pm, 7 pm to 11 pm
Saturday & Sunday: 7 pm to 11 pm
Public Holidays: Closed
Last registration: one hour before closing time.
Walk-in clinic. Appointments not required.
Bring NRIC, Work Pass or Passport for registration.

Sexual risk (of HIV/STD/pregnancy), and what you can do before and after exposure.

Timeline Event / Available resources
HIV STD Pregnancy
Before exposure
Abstain from sex, Be faithful, or Condom use
Circumcision (males only)
(females only)
HIV PrEP (pre-exposure prophylaxis) STD vaccine:
- Hepatitis vaccine
- HPV vaccine
STD / HIV exposure
Unsafe sex / unprotected sex:
No condom / Condom broke / Condom slip
0-72 hours HIV prevention
HIV PEP (post-exposure prophylaxis) treatment
- Stop HIV infection after exposure.
STD testing
If STD symptoms appear, then do STD treatment.
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.
Emergency contraception
(females only)
2 weeks HIV DNA PCR test
1 month 20 minute SD Bioline HIV Ag/Ab Combo HIV rapid test:
- Fingerprick blood sampling.
3 months 20 minute OraQuick® HIV rapid test:
- Oral saliva or
- Fingerprick blood sampling.
Full & comprehensive STD testing
- Males: Do not urinate for at least 4 hours before arriving.
- Females: testing is more accurate when you are not menstruating.


Latest News

Association between human papillomavirus (HPV) DNA and micronuclei in normal cervical cytology
Tue, 23 Sep 2014 18:52:11 +0100 | Genetics and Molecular Biology
The aim of the present study was to investigate the association between HPV-DNA and micronucleus (MN) frequency in women with normal cervical cytology. A total of 158 normal cervical smears were analyzed cytologically. The HPV genome was amplified using the GP5+/bioGP6+ consensus primers. HPV-DNA of high-risk types 16, 18, 31, 33, 39, 45 and 59 were also investigated. Of the 158 samples, 20 (12.7%) and 47 (29.7%) were positive for HPV-DNA and MN, respectively. Evidence for MN was found in 11 out of 20 (55%) HPV-DNA positive samples and in 36 out of 138 (26.1%) HPV-DNA negative ones. MN presence was significantly higher in HPV-DNA positive samples (p = 0.016). On the other hand, the absence of MN observed in a considerable number of HPV-DNA negative samples (102) may be of great value in pr...

HPV vaccine 'should be given to boys'
Tue, 23 Sep 2014 12:01:16 +0100 | Nursing in Practice
The government has been urged to extend human papillomavirus vaccination to all boys

[Articles] Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study
Mon, 22 Sep 2014 23:48:24 +0100 | The Lancet Infectious Diseases
6 years after the initiation of the Australian HPV vaccination programme, we have detected a substantial fall in vaccine-targeted HPV genotypes in vaccinated women; a lower prevalence of vaccine-targeted types in unvaccinated women, suggesting herd immunity; and a possible indication of cross-protection against HPV types related to the vaccine-targeted types in vaccinated women. (Source: The Lancet Infectious Diseases)

[Corrections] Corrections
Mon, 22 Sep 2014 23:48:19 +0100 | The Lancet Infectious Diseases
Tabrizi SN, Brotherton JML, Kaldor JM, et al. Assessment of herd immunity and cross-protection after a human papillomavirus vaccination programme in Australia: a repeat cross-sectional study. Lancet Infect Dis 2014; 14: 958–66—In this Article, the figure key should have stated that the blue bars represent the prevaccine sample and the red bars represent the post vaccine sample. This correction has been made to the online version as of Aug 20, and the printed Article is correct. (Source: The Lancet Infectious Diseases)

[Comment] Postlicensure monitoring of HPV vaccination programmes
Mon, 22 Sep 2014 23:48:16 +0100 | The Lancet Infectious Diseases
In The Lancet Infectious Diseases, Sepehr Tabrizi and colleagues report data from a repeat cross-sectional study of vaccine-eligible women attending family planning clinics before and after quadrivalent human papillomavirus (HPV) vaccine introduction in Australia. The investigators previously reported declines in the prevalence of vaccine-targeted HPV types (HPV 6, 11, 16, and 18) in the period after the introduction of the vaccine using data from earlier years of this study. In the present analysis, they confirmed earlier findings and also investigated herd effects of HPV vaccination and crossprotection against non-vaccine-targeted HPV types. (Source: The Lancet Infectious Diseases)

Quantitative analysis of P16 gene CpG methylation in Uyghur patients with cervical squamous cell carcinoma and its relationship with HPV16 infection.
Mon, 22 Sep 2014 04:45:03 +0100 | Genetics and Molecular Research
Authors: Cheng JX, Yuan M, Li AL, Zhou P, Shen GQ, Zhang Y

Association between the standardized uptake value and high-risk HPV in hypopharyngeal squamous cell carcinoma.
Sat, 20 Sep 2014 01:15:10 +0100 | Acta Oto-Laryngologica
Conclusion: Median (18)F-FDG PET/CT maximum standardized uptake values (SUVmax) cut-off values of 7.9 or greater were associated with high-risk human papillomavirus (HPV) negativity in patients with hypopharyngeal squamous cell carcinoma (HPSCC). Furthermore, median (18)F-FDG PET/CT SUVmax cut-off values of 7.9 or greater and high-risk HPV negativity were associated with adverse outcomes.

Management of the neck in node-positive tonsillar cancer.
Sat, 20 Sep 2014 01:15:07 +0100 | Acta Oto-Laryngologica
Conclusion: Neck dissection (ND) may not be warranted for those patients with complete response in the neck. Human papillomavirus (HPV)-positive or -negative tumour does not affect this recommendation.

Many throat cancer patients can skip neck surgery
Wed, 17 Sep 2014 16:07:03 +0100 | ScienceDaily Headlines
Patients with human papillomavirus (HPV) -- the same virus associated with both cervical and head and neck cancer -- positive oropharyngeal cancer see significantly higher rates of complete response on a post-radiation neck dissection than those with HPV-negative oropharyngeal cancer, researchers report. (Source: ScienceDaily Headlines)

HPV urine test could screen for cervical cancer
Wed, 17 Sep 2014 11:00:00 +0100 | NHS News Feed